Human papillomavirus vaccine safety in Australia: Experience to date and issues for surveillance

Sexual Health

Volumn 7, Issue 3, 2010, Pages 320-324

  Gold, Michael S ^a   Buttery, Jim ^b   McIntyre, Peter ^c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

adverse events following immunisations; HPV vaccine; vaccine safety

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ADVERSE OUTCOME; ANAPHYLAXIS; APHASIA; AUSTRALIA; CLINICAL TRIAL; COLLAPSE; CONGENITAL MALFORMATION; CONVERSION DISORDER; DEMYELINATING DISEASE; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG MONITORING; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; DYSPNEA; GUILLAIN BARRE SYNDROME; HEAD INJURY; HEADACHE; HEART PALPITATION; HUMAN; INFECTION PREVENTION; INJECTION SITE REACTION; LICENSING; LIPOATROPHY; MALAISE; MOTOR NEURON DISEASE; MULTIPLE SCLEROSIS; MYELITIS; NAUSEA; PANCREATITIS; PAPILLOMAVIRUS INFECTION; PREGNANCY OUTCOME; PREVENTIVE HEALTH SERVICE; REVIEW; SCHOOL HEALTH SERVICE; SEIZURE; SPONTANEOUS ABORTION; STILLBIRTH; SYNCOPE; UNITED STATES; URTICARIA; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; WART VIRUS; WEAKNESS;

ADOLESCENT; ADULT; ANAPHYLAXIS; AUSTRALIA; CAUSALITY; CHILD; CONVERSION DISORDER; CROSS-SECTIONAL STUDIES; DRUG APPROVAL; DRUG TOXICITY; FEMALE; GUILLAIN-BARRE SYNDROME; HUMANS; MASS VACCINATION; MULTIPLE SCLEROSIS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRIMARY HEALTH CARE; PRODUCT SURVEILLANCE, POSTMARKETING; SCHOOL HEALTH SERVICES; SEIZURES; SEXUALLY TRANSMITTED DISEASES, VIRAL; SYNCOPE; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 77956022641     PISSN: 14485028     EISSN: None     Source Type: Journal    
DOI: 10.1071/SH09153     Document Type: Review

References (21)

1. Australian Government Department of Health and Ageing, Therapeutic Goods Administration. Human papillomavirus vaccine (GARDASIL). 2009. Available online at: alerts/medicines/gardasil.htm [verified November 2009].
2. Anonymous Scientific Discussion 2006. Available online at: http:// www.emea.europa.eu/humandocs/Humans/EPAR/gardasil/gardasil.htm [verified November 2009].
3. Postila V. Sample size required for detecting at least one case of an adverse event with different incidence rates. Vaccine 2004; 22: 2076-2079 doi:10.1016/j.vaccine.2004.01.020 (Pubitemid 38581084)
4. Aide Memoire on AEFI investigation. Available online at: http:// www.who.int/immunization-safety/publications/aefi/en/index.html [verified May 2010]
5. Lawrence G, Gold MS, Hill R, Deeks S, Glasswell A, McIntyre PB. Annual report: surveillance of adverse events following immunization in Australia, 2007. Commun Dis Intell 2008; 32: 371-387
6. Menzies R, Mahajan D, Gold MS, Roomiani I, McIntyre P, Lawrence G. Annual report: surveillance of adverse events following immunisation in Australia, 2008. Commun Dis Intell 2009; 33: 365-381
7. Brotherton JM, Gold MS, Kemp AS, McIntyre PB, Burgess MA, Campbell-Lloyd S, et al. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ 2008; 179: 525-33.doi:10.1503/cmaj.080916
8. Buttery JP, Madin S, Crawford NW, Elia S, La Vincente S, Hanieh S, et al. Mass psychogenic response to human papillomavirus vaccination. Med J Aust 2008; 189: 261-262
9. Ojaimi S, Buttery JP, Korman TM. Quadrivalent human papillomavirus recombinant vaccine associated lipoatrophy. Vaccine 2009; 27: 4876-4878 doi:10.1016/j.vaccine.2009.06.026
10. Sutton I, Lahoria R, Tan I, Clouston P, Barnett M. CNS demyelination and quadrivalent HPV vaccination. Mult Scler 2009; 15: 116-119 doi:10.1177/ 1352458508096868
11. Kang LW, Crawford N, Tang ML, Buttery J, Royle J, Gold M, et al. Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study. BMJ 2008; 337: a2642. doi:10.1136/bmj.a2642
12. Das A, Chang D, Biankin AV, Merrett ND. Pancreatitis following human papillomavirus vaccination. MJA 2008; 189: 178.
13. Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009; 302: 750-7.doi:10.1001/jama.2009.1201
14. Rüggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J, Friedlander S, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007; 25: 5675-5684 doi:10.1016/j.vaccine.2007. 02.064 (Pubitemid 47049764)
15. DSouza RM, Campbell-Lloyd S, Isaacs D, Gold M, Burgess M, Turnbull F, et al. Adverse events following immunisation associated with the 1998 Australian measles control campaign. Commun Dis Intell 2000; 24: 27-33.
16. Siegrist CA, Lewis EA, Eskola J, Evans S, Black SB. Human papillomavirus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J 2007; 26: 979-984 doi:10.1097/INF.0b013e318149dfea (Pubitemid 350287577)
17. Lucas RM, Ponsonby AL, McMichael AJ, van der Mei I, Chapman C, Coulthard A, et al. Observational analytic studies in multiple sclerosis: controlling bias through study design and conduct. The Australian Multicentre Study of Environment and Immune Function. Mult Scler 2007; 13: 827-39. doi:10.1177/1352458507 077174
18. Tourbah A, Gout O, Liblau R, Lyon-Caen O, Bougniot C, Iba- Zizen MT, Cabanis EA. Encephalitis after hepatitis B vaccination: recurrent disseminated encephalitis or MS? Neurology 1999; 53: 396-401.
19. DeStefano F, Verstraeten T, Chen RT. Hepatitis B vaccine and risk of multiple sclerosis. Expert Rev Vaccines 2002; 1: 461-466 doi:10.1586/ 14760584.1.4.461
20. Watson M, Shaw D, Molchanoff L, McInnes C. Challenges, lessons learned and results following the implementation of a human papillomavirus school vaccination program in South Australia. Aust NZ J Public Health 2009; 33: 365-370 doi:10.1111/j.1753-6405. 2009.00409.x
21. Brotherton JM, Deeks SL, Campbell-Lloyd S, Misrachi A, Passaris I, Peterson K, et al. Interim estimates of human papillomavirus accination coverage in the school-based program in Australia. Commun Dis Intell 2008; 32: 457-461